The United States Patent and Trademark Office (USPTO) has granted patent US12582711B2, titled "RNA-based adjuvant to enhance the immune response to vaccines and therapeutics," to IMMUNESURE LLC. The patent, which has an effective date of March 24, 2026, covers antisense inhibitor adjuvant compositions comprising modified nucleotide sequences complementary to Homo sapiens interleukin 10 (IL-10) or interleukin 10 receptor alpha (IL-10RA) genes, along with methods for their use.

This patent grant signifies a new intellectual property asset in the field of vaccine and therapeutic development. While not a regulatory rule imposing obligations, it represents a novel technological advancement that may influence future product development and regulatory submissions for immunotherapies and vaccines. Companies operating in the biotechnology and pharmaceutical sectors, particularly those involved in vaccine adjuvant research, should be aware of this granted patent as it may impact their freedom to operate or present opportunities for licensing or collaboration.